Pay in 4 interest-free payments of $6.53 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
ALA is unique because it is both
(Lausanne) 12, 741764
Critical safety considerations for laboratory use include potential immunogenicity concernswith peptide therapeutics commonly showing injection site reactions (20-40% with subcutaneous administration) and possible antidrug antibody formationalong with theoretical concerns that pro-angiogenic properties could potentially influence experimental tumor models, requiring appropriate controls in oncology-related research
Continuous glucose monitoring is necessary to anticipate dysglycemia, whereas triglyceride level monitoring is essential to anticipate filter clotting, and electrolyte correction should be performed according to patient needs
US$ 21.10
US$ 27.20
US$ 21.85
